All In Biotech

Drug Trial Radar · NCT07066722

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

A Phase 1, Open-Label Study to Evaluate the Relative Bioavailability and the Effect of Food on VH4524184 Tablet Formulations, and to Evaluate the Potential for VH4524184 Drug-Drug-Interactions in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

126

Actual

Start

Jul 7, 2025

Primary completion

Dec 17, 2025

Study completion Dec 17, 2025

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Jul 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of the study is to gather information on how the drug behaves in healthy adults, how it is absorbed, and how it interacts when taken with other medicines.

Conditions

  • HIV Infections

Interventions

  • VH4524184Drug

    VH4524184 will be administered.

  • ItraconazoleDrug

    Itraconazole will be administered.

  • RifabutinDrug

    Rifabutin will be administered.

  • PhenytoinDrug

    Extended phenytoin sodium will be administered.

  • MetforminDrug

    Metformin will be administered.

  • DigoxinDrug

    Digoxin will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Maximum plasma concentration (Cmax) for VH4524184Time frame: Up to Day 18
  2. Part 1: Area under the concentration-time curve from 0 to tau (AUC0-t) for VH4524184Time frame: Up to day 18
  3. Part 1: Area under the concentration-time curve from 0 to infinity (AUC0-inf) for VH4524184Time frame: Up to day 18
  4. Part 2: Cmax for VH4524184Time frame: At Day 1, Day 14, Day 19 and Day 22
  5. Part 2: AUC0-t of VH4524184Time frame: At Day 1, Day 14, Day 19 and Day 22
  6. Part 2: AUC0-inf of VH4524184Time frame: At Day 1, Day 14, Day 19 and Day 22
  7. Part 2: Cmax for metforminTime frame: At Day 1 and Day 15
  8. Part 2: AUC0-t for metforminTime frame: At Day 1 and Day 15
  9. Part 2: Cmax for DigoxinTime frame: At Day 1 and Day 15
  10. Part 2: AUC0-t for DigoxinTime frame: At Day 1 and Day 15

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Lenexa, Kansas

  • GSK Investigational Site

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.